Hints and tips:
Related Special Reports
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...The UK-based pharmaceutical group reported revenue of $12.7bn, well ahead of consensus estimates of $11.9bn....
...But the groups “would prefer to solve their own problems, as opposed to have politicians solve it”, he said....
...A growing number of Mexicans consume recreational drugs, but the top voter concern is the violence driven by conflict between the fragmented groups....
...insurers to cover the drug....
...Pharma groups are optimistic about the potential for new weight loss and diabetes drugs known as GLP-1s to treat liver diseases....
...Nasdaq and London Stock Exchange Group....
...Leqembi slowed cognitive decline by 27 per cent compared with the placebo group in a phase 3 trial....
...“That is what ends up fuelling the skirmishes between 46 different groups in Rosario.”...
...The European Commission is the first authority to approve the treatment, which is likely to be used in a relatively narrow group of serious cases to reduce the risk it will trigger a surge in anti-microbial...
...While the drug being developed by Swiss pharmaceutical group Roche has been tested on only one type of bacteria, the way it works suggests it could be effective against other microbes — and encourage much-needed...
...“The FDA has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab,” the Indianapolis-based group said on Friday....
...Publication of the names, proposed by the Harvard Alumni Association ahead of a vote in May, comes as tensions over academic freedom and diversity policies on campus intensified on Friday after a group of...
...Leqembi, an Alzheimer’s drug produced by Biogen and Japan-based pharma group Eisai, received approval from the FDA in July last year....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...“Drug trafficking gangs such as Los Choneros, many with ties to powerful drug cartels in Mexico, threaten the lives and livelihoods of communities in Ecuador and throughout the region,” Brian Nelson, the...
...NHS England, NICE, Daiichi Sankyo and AstraZeneca have failed people living with the disease.” Scotland approved the drug in December....
...Orchard, a UK-based biotech that was recently bought by Japanese pharmaceutical group Kyowa Kirin, argued that the lack of other treatments for MLD justified the price....
...They certainly should after the entertainment group announced a long-expected go-private sale to its existing majority shareholders this week. The deal values Endeavor’s equity at $13bn....
...Both groups are studying the drugs as treatments for different types of fatty liver diseases....
...Eli Lilly is racing to secure the services of outsourcers to boost production of its obesity drug Zepbound, as the US pharmaceutical group rolls out its rival to Danish group Novo Nordisk’s blockbuster appetite...
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
...Goldman Sachs and Citadel Securities are among a group of 10 large trading groups backing bond pioneer Howard Lutnick’s renewed tilt on CME’s monopoly on the US Treasury futures market....
...But within a year of the US Food and Drug Administration’s 2021 approval of the weight-loss drugs known as GLP-1 agonists, the threat of them breaking WW’s business model became clear....
International Edition